The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A common polymorphism in the LDL receptor gene has multiple effects on LDL receptor function
Abstract
A common synonymous single nucleotide polymorphism in exon 12 of the low-density lipoprotein receptor (LDLR) gene, rs688, has been associated with increased plasma total and LDL cholesterol in several populations. Using immortalized lymphoblastoid cell lines from a healthy study population, we confirmed an earlier report that the minor allele of rs688 is associated with increased exon 12 alternative splicing (P < 0.05) and showed that this triggered nonsense-mediated decay (NMD) of the alternatively spliced LDLR mRNA. However, since synonymous single nucleotide polymorphisms may influence structure and function of the encoded proteins by co-translational effects, we sought to test whether rs688 was also functional in the full-length mRNA. In HepG2 cells expressing LDLR cDNA constructs engineered to contain the major or minor allele of rs688, the latter was associated with a smaller amount of LDLR protein at the cell surface (-21.8 ± 0.6%, P = 0.012), a higher amount in the lysosome fraction (+25.7 ± 0.3%, P = 0.037) and reduced uptake of fluorescently labeled LDL (-24.3 ± 0.7%, P < 0.01). Moreover, in the presence of exogenous proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces cellular LDL uptake by promoting lysosomal degradation of LDLR, the minor allele resulted in reduced capacity of a PCSK9 monoclonal antibody to increase LDL uptake. These findings are consistent with the hypothesis that rs688, which is located in the β-propeller region of LDLR…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
LDLRs are either transported to lysosomes for degradation or recycled to the cell surface for reuse.
“LDLRs are then either transported to lysosomes for degradation or recycled to the cell surface for reuse2.”
From Phosphatidylinositol-(4,5)-Bisphosphate Regulates Plasma Cholesterol Through LDL (Low-Density Lipoprotein) Receptor Lysosomal Degradation (2020) · cites this paper as [2]
Citations
Cites
Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
Stein, E. A., Mellis, S., Yancopoulos, G. D., Stahl, N., Logan, D., Smith, W. B., Lisbon, E., Gutierrez, M., Webb, C., Wu, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105803 · Cited by 664
Flagged first, then by citations
Research works printed but not linked: 35
- Goldstein, 1982, Receptor-mediated endocytosis and the cellular uptake of low density lipoprotein, Ciba Foundation symposium, 77
- Brown, 1986, A receptor-mediated pathway for cholesterol homeostasis, Science, 232, 34, 10.1126/science.3513311 · DOI · Paper page
- Teslovich, 2010, Biological, clinical and population relevance of 95 loci for blood lipids, Nature, 466, 707, 10.1038/nature09270 · DOI · Paper page
- Boright, 1998, Association and linkage of LDLR gene variation with variation in plasma low density lipoprotein cholesterol, Journal of human genetics, 43, 153, 10.1007/s100380050060 · DOI
- Fu, 2001, A common mutation of low-density lipoprotein receptor gene is associated with essential hypertension among Japanese, Journal of human hypertension, 15, 125, 10.1038/sj.jhh.1001132 · DOI
- Schaefer, 1994, Effects of gender and menopausal status on the association of apolipoprotein E phenotype with plasma lipoprotein levels. Results from the Framingham Offspring Study, Arterioscler Thromb, 14, 1105, 10.1161/01.ATV.14.7.1105 · DOI
- Zhu, 2007, A common polymorphism decreases low-density lipoprotein receptor exon 12 splicing efficiency and associates with increased cholesterol, Hum Mol Genet, 16, 1765, 10.1093/hmg/ddm124 · DOI
- Zou, 2008, Sex-dependent association of a common low-density lipoprotein receptor polymorphism with RNA splicing efficiency in the brain and Alzheimer's disease, Human molecular genetics, 17, 929, 10.1093/hmg/ddm365 · DOI · Paper page
- Sanchez-Sanchez, 2008, Nonsense-mediated decay: paving the road for genome diversification, Bioessays, 30, 926, 10.1002/bies.20825 · DOI
- Wen, 2008, Nonsense-mediated mRNA decay, Biochemical Society transactions, 36, 514, 10.1042/BST0360514 · DOI
- Waldman, 2011, Selection for translation efficiency on synonymous polymorphisms in recent human evolution, Genome biology and evolution, 3, 749, 10.1093/gbe/evr076 · DOI
- Xu, 2010, Screening of Kozak-motif-located SNPs and analysis of their association with human diseases, Biochemical and biophysical research communications, 392, 89, 10.1016/j.bbrc.2010.01.002 · DOI
- Nackley, 2009, Low enzymatic activity haplotypes of the human catechol-O-methyltransferase gene: enrichment for marker SNPs, PloS one, 4, 10.1371/journal.pone.0005237 · DOI
- Lee, 2008, F-SNP: computationally predicted functional SNPs for disease association studies, Nucleic acids research, 36, D820, 10.1093/nar/gkm904 · DOI
- Kimchi-Sarfaty, 2007, A "silent" polymorphism in the MDR1 gene changes substrate specificity, Science, 315, 525, 10.1126/science.1135308 · DOI · Paper page
- Wang, 2005, Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability, Pharmacogenetics and genomics, 15, 693, 10.1097/01.fpc.0000178311.02878.83 · DOI
- Zhang, 2008, Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor, Proceedings of the National Academy of Sciences of the United States of America, 105, 13045, 10.1073/pnas.0806312105 · DOI · Paper page
- Beglova, 2004, Structural features of the low-density lipoprotein receptor facilitating ligand binding and release, Biochemical Society transactions, 32, 721, 10.1042/BST0320721 · DOI
- Schell, 2002, Integration of splicing, transport and translation to achieve mRNA quality control by the nonsense-mediated decay pathway, Genome biology, 3, 10.1186/gb-2002-3-3-reviews1006 · DOI
- Tveten, 2012, Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification, Human molecular genetics, 21, 1402, 10.1093/hmg/ddr578 · DOI · Paper page
- Martinelli, 2010, Polymorphisms at LDLR locus may be associated with coronary artery disease through modulation of coagulation factor VIII activity and independently from lipid profile, Blood, 116, 5688, 10.1182/blood-2010-03-277079 · DOI
- Linsel-Nitschke, 2008, Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease–a Mendelian Randomisation study, PloS one, 3, 10.1371/annotation/9f64c41a-8cf6-40f2-8988-0d48b04dd8cb · DOI
- Holla, 2009, Nonsense-mediated decay of human LDL receptor mRNA, Scandinavian journal of clinical and laboratory investigation, 69, 409, 10.1080/00365510802707163 · DOI
- Angov, 2011, Codon usage: nature's roadmap to expression and folding of proteins, Biotechnology journal, 6, 650, 10.1002/biot.201000332 · DOI
- Bartoszewski, 2010, A synonymous single nucleotide polymorphism in DeltaF508 CFTR alters the secondary structure of the mRNA and the expression of the mutant protein, The Journal of biological chemistry, 285, 28741, 10.1074/jbc.M110.154575 · DOI
- Tsai, 2008, Synonymous mutations and ribosome stalling can lead to altered folding pathways and distinct minima, Journal of molecular biology, 383, 281, 10.1016/j.jmb.2008.08.012 · DOI
- Bulmer, 1987, Coevolution of codon usage and transfer RNA abundance, Nature, 325, 728, 10.1038/325728a0 · DOI
- Surdo, 2011, Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH, EMBO reports, 12, 1300, 10.1038/embor.2011.205 · DOI · Paper page
- Zhang, 2012, An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes, International journal of biological sciences, 8, 310, 10.7150/ijbs.3524 · DOI
- Heeren, 1999, Nonphysiological overexpression of low-density lipoprotein receptors causes pathological intracellular lipid accumulation and the formation of cholesterol and cholesteryl ester crystals in vitro, J Mol Med (Berl), 77, 735, 10.1007/s001099900045 · DOI
- Roth, 2012, Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia, The New England journal of medicine, 10.1056/NEJMoa1201832 · DOI
- Pressman, 1991, Epstein-Barr virus transformation of cryopreserved lymphocytes: prolonged experience with technique, American journal of human genetics, 49, 467
- Medina, 2008, Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin, Circulation, 118, 355, 10.1161/CIRCULATIONAHA.108.773267 · DOI
- Medina, 2011, Coordinately regulated alternative splicing of genes involved in cholesterol biosynthesis and uptake, PloS one, 6, 10.1371/journal.pone.0019420 · DOI
- Chan, 2009, A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates, Proceedings of the National Academy of Sciences of the United States of America, 106, 9820, 10.1073/pnas.0903849106 · DOI · Paper page
Cited by
Sorted by citations
PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9
Tavori, H., Giunzioni, I., & Fazio, S. (2015) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000137 · Cited by 30
Transmembrane Protein 55B Is a Novel Regulator of Cellular Cholesterol Metabolism
Medina, M. W., Bauzon, F., Naidoo, D., Theusch, E., Stevens, K., Schilde, J., Schubert, C., Mangravite, L. M., Rudel, L. L., Temel, R. E., et al. (2014) · Arteriosclerosis, Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.302806 · Cited by 24
Self-citationAlirocumab: PCSK9 inhibitor for LDL cholesterol reduction
Tavori, H., Melone, M., & Rashid, S. (2014) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2014.954551 · Cited by 21
Qin, Y., Ting, F., Kim, M. J., Strelnikov, J., Harmon, J., Gao, F., Dose, A., Teng, B.-B., Alipour, M. A., Yao, Z., et al. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.120.314033 · Cited by 18
Self-citation
Metadata
- Authors
- Gao, F., Ihn, H. E., Medina, M. W., & Krauss, R. M.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-01-07
- Volume
- 22
- Issue
- 7
- Pages
- 1424-1431
- ISSN
- 1460-2083
- 0964-6906
- Cited by
- 36
- References
- 1
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review